100, Stuart St

Boston,

MA,

USA,

ZIP: 02116

Phone:

Immune tolerance offers a transformative approach to autoimmune diseases treatment and holds the power to modify the course of disease progression and significantly improve the quality of life for patients.

For 7 years, the 8th Antigen-Specific Immune Tolerance Summit has been at the forefront of innovative and novel approaches to immunology and inflammation and facilitated the development of new industry connections, research partnerships and seed investment across the immune tolerance field.

In 2025, this highly anticipated meeting will delve further into the complex reality of inducing immune tolerance as the landscape evolves with Diamyd, Annokion, COUR and more being the custodians of rapidly progressing clinical tirals.

From antigen selection, to establishing biomarkers of tolerance to brand-new clinical readouts, join 120+ autoimmune, immunology and inflammation experts at this timely and comprehensive network to continue to drive the momentum in the field.

With new companies, new antigens, and new disease targets, you can't miss this opportunity to capitalize on the wealth of opportunities in antigen-specific immune tolerance drug development and contribute to the transformation of autoimmune disease treatment.

URLs:
Tickets: https://go.evvnt.com/2706824-1?pid=1052
Brochure: https://go.evvnt.com/2706824-2?pid=1052

Prices:
Drug Developer - Conference + Pre-Conference Seminar Day: USD 5046.00,
Academic - Conference + Pre-Conference Seminar Day: USD 4346.00,
Solution Provider - Conference + Pre-Conference Seminar Day: USD 5746.00,
Drug Developer - Conference Only: USD 3099.00,
Academic - Conference Only: USD 2699.00,
Solution Provider - Conference Only: USD 3799.00

Speakers: Aaron Winkler, Immune Tolerance Lead and Research Fellow, Inflammation and Immunology, Pfizer, Adam Elhofy, Vice President - Research and Collaborations, COUR Pharmaceuticals, Brian Zhou Associate, Director - Immunology Venture Science, Eli Lilly and Co., Caroline Gronwall, Associate Professor, Karolinska Institutet, Charlotte Fribert, Chief Executive Officer, Toleranzia, Chris Tam, CEO, Integrated Nanotherapeutics, Dan Shelly, Chief Business Officer, PolTREG, David Easterhoff, Director, Moderna, Fiona McCann, Associate Director - Pipeline Biology, Immucore, Geoffrey Lynn, Senior Vice President - Synthetic Immunotherapies, Barinthus Biotherapeutics, Jessica Kenison, Director of Immunology, Immunocodex, Joanne Tan, Senior Vice President - R and D, Parvus Therapeutics, Joe Podojil, Director - Immunology, COUR Pharmaceuticals, Jose Carballido, Executive Director - Translational Medicine and Preclinical Safety, Novartis, Ken Howard, Associate Professor, Aarhus University, Kristie Grebe, Chief Scientific Officer, Anokion, Lauren Higdon, Director - Marker and Discovery Research, Immune Tolerance Network, Martina Sassone Corsi, Associate Director - Discovery, GentiBio, Melissa Matzelle, Associate Director - Immunology S and E, Abbvie, Michael Birnbaum, Associate Professor - Biological Engineering, Massachusetts Institute of Technology, Michael Birnbaum, Associate Professor - Biological Engineering, Massachusetts Institute of Technology, Poul Sorensen, Partner and Entrepreneur-in-Residence, ARGO Bio, Tracey Lodie, Chief Development Officer, GRO Bio, Ulf Hannelius, Chief Executive Officer, Diamyd Medical, Weston Daniel, Chief Development Officer, EVOQ Therapeutics